These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
373 related articles for article (PubMed ID: 32695676)
1. Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients. Tao Z; Li T; Feng Z; Liu C; Shao Y; Zhu M; Gong C; Wang B; Cao J; Wang L; Du Y; Lizaso A; Li B; Zhang J; Hu X Front Oncol; 2020; 10():1023. PubMed ID: 32695676 [No Abstract] [Full Text] [Related]
2. Genetic alterations and their association with clinicopathologic characteristics in advanced breast carcinomas: focusing on clinically actionable genetic alterations. Freitag CE; Mei P; Wei L; Parwani AV; Li Z Hum Pathol; 2020 Aug; 102():94-103. PubMed ID: 32445652 [TBL] [Abstract][Full Text] [Related]
3. Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts. Zhang G; Wang Y; Chen B; Guo L; Cao L; Ren C; Wen L; Li K; Jia M; Li C; Mok H; Chen X; Wei G; Lin J; Zhang Z; Hou T; Han-Zhang H; Liu C; Liu H; Liu J; Balch CM; Meric-Bernstam F; Liao N Ann Transl Med; 2019 Apr; 7(8):179. PubMed ID: 31168460 [TBL] [Abstract][Full Text] [Related]
4. Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Martínez-Sáez O; Chic N; Pascual T; Adamo B; Vidal M; González-Farré B; Sanfeliu E; Schettini F; Conte B; Brasó-Maristany F; Rodríguez A; Martínez D; Galván P; Rodríguez AB; Martinez A; Muñoz M; Prat A Breast Cancer Res; 2020 May; 22(1):45. PubMed ID: 32404150 [TBL] [Abstract][Full Text] [Related]
5. Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers. Lee S; Kim HY; Jung YJ; Jung CS; Im D; Kim JY; Lee SM; Oh SH Curr Probl Cancer; 2022 Apr; 46(2):100843. PubMed ID: 35180531 [TBL] [Abstract][Full Text] [Related]
6. Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients. Liao H; Zhang J; Zheng T; Liu X; Zhong J; Shao B; Dong X; Wang X; Du P; King BL; Jia S; Yu J; Li H J Transl Med; 2022 May; 20(1):211. PubMed ID: 35562750 [TBL] [Abstract][Full Text] [Related]
7. Genomic alteration profile and PD-L1 expression among different breast cancer subtypes in Chinese population and their correlations. Li K; Cao L; Li C; Wu J; Chen B; Zhang G; Li X; Wen L; Jia M; Wei G; Lin J; Li Y; Zhang Y; Mok H; Ren C; Wang Y; Qi X; Guo L; Che Y; Liao N Cancer Med; 2023 Mar; 12(5):5195-5208. PubMed ID: 36404592 [TBL] [Abstract][Full Text] [Related]
8. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Mosele F; Stefanovska B; Lusque A; Tran Dien A; Garberis I; Droin N; Le Tourneau C; Sablin MP; Lacroix L; Enrico D; Miran I; Jovelet C; Bièche I; Soria JC; Bertucci F; Bonnefoi H; Campone M; Dalenc F; Bachelot T; Jacquet A; Jimenez M; André F Ann Oncol; 2020 Mar; 31(3):377-386. PubMed ID: 32067679 [TBL] [Abstract][Full Text] [Related]
9. Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations. Miyashita M; Bell JSK; Wenric S; Karaesmen E; Rhead B; Kase M; Kaneva K; De La Vega FM; Zheng Y; Yoshimatsu TF; Khramtsova G; Liu F; Zhao F; Howard FM; Nanda R; Beaubier N; White KP; Huo D; Olopade OI Breast Cancer Res; 2023 May; 25(1):58. PubMed ID: 37231433 [TBL] [Abstract][Full Text] [Related]
10. Distinct Somatic Alteration Features Identified by Gene Panel Sequencing in Korean Triple-Negative Breast Cancer with High Ki67 Expression. Sun WY; Lee J; Kim BK; Kim JO; Park J Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33804295 [TBL] [Abstract][Full Text] [Related]
11. Significance of Multi-Cancer Genome Profiling Testing for Breast Cancer: A Retrospective Analysis of 3326 Cases from Japan's National Database. Kawabata K; Nishikubo H; Kanei S; Aoyama R; Tsukada Y; Sano T; Imanishi D; Sakuma T; Maruo K; Yamamoto Y; Wang Q; Zhu Z; Fan C; Yashiro M Genes (Basel); 2024 Jun; 15(6):. PubMed ID: 38927728 [No Abstract] [Full Text] [Related]
12. Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance. Hu ZY; Xie N; Tian C; Yang X; Liu L; Li J; Xiao H; Wu H; Lu J; Gao J; Hu X; Cao M; Shui Z; Xiao M; Tang Y; He Q; Chang L; Xia X; Yi X; Liao Q; Ouyang Q EBioMedicine; 2018 Jun; 32():111-118. PubMed ID: 29807833 [TBL] [Abstract][Full Text] [Related]
13. Characterization of Frequently Mutated Cancer Genes and Tumor Mutation Burden in Chinese Breast Cancer. Xiao W; Zhang G; Chen B; Chen X; Wen L; Lai J; Li X; Li M; Liu H; Liu J; Han-Zhang H; Lizaso A; Liao N Front Oncol; 2021; 11():618767. PubMed ID: 33968723 [TBL] [Abstract][Full Text] [Related]
14. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer. Liang X; Vacher S; Boulai A; Bernard V; Baulande S; Bohec M; Bièche I; Lerebours F; Callens C Breast Cancer Res; 2018 Aug; 20(1):88. PubMed ID: 30086764 [TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Basho RK; de Melo Gagliato D; Ueno NT; Wathoo C; Chen H; Shariati M; Wei C; Alvarez RH; Moulder SL; Sahin AA; Roy-Chowdhuri S; Chavez-MacGregor M; Litton JK; Valero V; Luthra R; Zeng J; Shaw KR; Mendelsohn J; Mills GB; Tripathy D; Meric-Bernstam F Oncotarget; 2016 Nov; 7(47):76362-76373. PubMed ID: 27806348 [TBL] [Abstract][Full Text] [Related]
16. Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial. Loibl S; Treue D; Budczies J; Weber K; Stenzinger A; Schmitt WD; Weichert W; Jank P; Furlanetto J; Klauschen F; Karn T; Pfarr N; von Minckwitz G; Möbs M; Jackisch C; Sers C; Schneeweiss A; Fasching PA; Schem C; Hummel M; van Mackelenbergh M; Nekljudova V; Untch M; Denkert C Clin Cancer Res; 2019 Jul; 25(13):3986-3995. PubMed ID: 30979740 [TBL] [Abstract][Full Text] [Related]
17. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study. Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307 [TBL] [Abstract][Full Text] [Related]
18. ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC). Ferrando L; Vingiani A; Garuti A; Vernieri C; Belfiore A; Agnelli L; Dagrada G; Ivanoiu D; Bonizzi G; Munzone E; Lippolis L; Dameri M; Ravera F; Colleoni M; Viale G; Magnani L; Ballestrero A; Zoppoli G; Pruneri G PLoS Genet; 2023 Jan; 19(1):e1010563. PubMed ID: 36595552 [TBL] [Abstract][Full Text] [Related]
19. Landscape of circulating tumour DNA in metastatic breast cancer. Davis AA; Jacob S; Gerratana L; Shah AN; Wehbe F; Katam N; Zhang Q; Flaum L; Siziopikou KP; Platanias LC; Gradishar WJ; Behdad A; Cristofanilli M EBioMedicine; 2020 Aug; 58():102914. PubMed ID: 32707446 [TBL] [Abstract][Full Text] [Related]
20. Genomic and transcriptomic landscape of HER2-low breast cancer. Bansal R; Adeyelu T; Elliott A; Walker P; Bustos MA; Rodriguez E; Accordino MK; Meisel J; Gatti-Mays ME; Hsu E; Lathrop K; Kaklamani V; Oberley M; Sledge G; Sammons SL; Graff SL Breast Cancer Res Treat; 2024 Sep; ():. PubMed ID: 39302579 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]